FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088446089> ?p ?o ?g. }

• W3088446089 endingPage "m3342" @default.
• W3088446089 startingPage "m3342" @default.
• W3088446089 abstract "Abstract Objective To compare the risk of cardiovascular events between sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors among people with type 2 diabetes in a real world context of clinical practice. Design Multi-database retrospective cohort study using a prevalent new user design with subsequent meta-analysis. Setting Canadian Network for Observational Drug Effect Studies (CNODES), with administrative healthcare databases from seven Canadian provinces and the United Kingdom, 2013-18. Population 209 867 new users of a SGLT2 inhibitor matched to 209 867 users of a DPP-4 inhibitor on time conditional propensity score and followed for a mean of 0.9 years. Main outcome measures The primary outcome was major adverse cardiovascular events (MACE, a composite of myocardial infarction, ischaemic stroke, or cardiovascular death). Secondary outcomes were the individual components of MACE, heart failure, and all cause mortality. Cox proportional hazards models were used to estimate site specific adjusted hazards ratios and 95% confidence intervals, comparing use of SGLT2 inhibitors with use of DPP-4 inhibitors in an as treated approach. Site specific results were pooled using random effects meta-analysis. Results Compared with DPP-4 inhibitors, SGLT2 inhibitors were associated with decreased risks of MACE (incidence rate per 1000 person years: 11.4 v 16.5; hazard ratio 0.76, 95% confidence interval 0.69 to 0.84), myocardial infarction (5.1 v 6.4; 0.82, 0.70 to 0.96), cardiovascular death (3.9 v 7.7; 0.60, 0.54 to 0.67), heart failure (3.1 v 7.7; 0.43, 0.37 to 0.51), and all cause mortality (8.7 v 17.3; 0.60, 0.54 to 0.67). SGLT2 inhibitors had more modest benefits for ischaemic stroke (2.6 v 3.5; 0.85, 0.72 to 1.01). Similar benefits for MACE were observed with canagliflozin (0.79, 0.66 to 0.94), dapagliflozin (0.73, 0.63 to 0.85), and empagliflozin (0.77, 0.68 to 0.87). Conclusions In this large observational study conducted in a real world clinical practice context, the short term use of SGLT2 inhibitors was associated with a decreased risk of cardiovascular events compared with the use of DPP-4 inhibitors. Trial registration ClinicalTrials.gov NCT03939624 ." @default.
• W3088446089 created "2020-10-01" @default.
• W3088446089 creator A5002024158 @default.
• W3088446089 creator A5007204967 @default.
• W3088446089 creator A5007497866 @default.
• W3088446089 creator A5008217187 @default.
• W3088446089 creator A5017432882 @default.
• W3088446089 creator A5029683846 @default.
• W3088446089 creator A5029870762 @default.
• W3088446089 creator A5042574911 @default.
• W3088446089 creator A5042964192 @default.
• W3088446089 creator A5048225022 @default.
• W3088446089 creator A5068337009 @default.
• W3088446089 creator A5072519261 @default.
• W3088446089 creator A5073931268 @default.
• W3088446089 creator A5081987341 @default.
• W3088446089 creator A5082999537 @default.
• W3088446089 creator A5087573242 @default.
• W3088446089 date "2020-09-23" @default.
• W3088446089 modified "2023-10-11" @default.
• W3088446089 title "Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study" @default.
• W3088446089 cites W1849521086 @default.
• W3088446089 cites W2013047715 @default.
• W3088446089 cites W2026656096 @default.
• W3088446089 cites W2042104538 @default.
• W3088446089 cites W2064130493 @default.
• W3088446089 cites W2082081076 @default.
• W3088446089 cites W2119852447 @default.
• W3088446089 cites W2127854619 @default.
• W3088446089 cites W2142830692 @default.
• W3088446089 cites W2146264128 @default.
• W3088446089 cites W2340143475 @default.
• W3088446089 cites W2519686100 @default.
• W3088446089 cites W2581368499 @default.
• W3088446089 cites W2614137535 @default.
• W3088446089 cites W2626446274 @default.
• W3088446089 cites W2768451744 @default.
• W3088446089 cites W2780645176 @default.
• W3088446089 cites W2782920834 @default.
• W3088446089 cites W2793906475 @default.
• W3088446089 cites W2796063363 @default.
• W3088446089 cites W2802564813 @default.
• W3088446089 cites W2805417982 @default.
• W3088446089 cites W2884954235 @default.
• W3088446089 cites W2900149048 @default.
• W3088446089 cites W2900413769 @default.
• W3088446089 cites W2900732862 @default.
• W3088446089 cites W2954774129 @default.
• W3088446089 cites W2970848622 @default.
• W3088446089 cites W2973090108 @default.
• W3088446089 cites W2976129020 @default.
• W3088446089 cites W2989141930 @default.
• W3088446089 cites W2128110408 @default.
• W3088446089 doi "https://doi.org/10.1136/bmj.m3342" @default.
• W3088446089 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8009082" @default.
• W3088446089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32967856" @default.
• W3088446089 hasPublicationYear "2020" @default.
• W3088446089 type Work @default.
• W3088446089 sameAs 3088446089 @default.
• W3088446089 citedByCount "59" @default.
• W3088446089 countsByYear W30884460892020 @default.
• W3088446089 countsByYear W30884460892021 @default.
• W3088446089 countsByYear W30884460892022 @default.
• W3088446089 countsByYear W30884460892023 @default.
• W3088446089 crossrefType "journal-article" @default.
• W3088446089 hasAuthorship W3088446089A5002024158 @default.
• W3088446089 hasAuthorship W3088446089A5007204967 @default.
• W3088446089 hasAuthorship W3088446089A5007497866 @default.
• W3088446089 hasAuthorship W3088446089A5008217187 @default.
• W3088446089 hasAuthorship W3088446089A5017432882 @default.
• W3088446089 hasAuthorship W3088446089A5029683846 @default.
• W3088446089 hasAuthorship W3088446089A5029870762 @default.
• W3088446089 hasAuthorship W3088446089A5042574911 @default.
• W3088446089 hasAuthorship W3088446089A5042964192 @default.
• W3088446089 hasAuthorship W3088446089A5048225022 @default.
• W3088446089 hasAuthorship W3088446089A5068337009 @default.
• W3088446089 hasAuthorship W3088446089A5072519261 @default.
• W3088446089 hasAuthorship W3088446089A5073931268 @default.
• W3088446089 hasAuthorship W3088446089A5081987341 @default.
• W3088446089 hasAuthorship W3088446089A5082999537 @default.
• W3088446089 hasAuthorship W3088446089A5087573242 @default.
• W3088446089 hasBestOaLocation W30884460891 @default.
• W3088446089 hasConcept C126322002 @default.
• W3088446089 hasConcept C127413603 @default.
• W3088446089 hasConcept C167135981 @default.
• W3088446089 hasConcept C201903717 @default.
• W3088446089 hasConcept C207103383 @default.
• W3088446089 hasConcept C2778198053 @default.
• W3088446089 hasConcept C2780400711 @default.
• W3088446089 hasConcept C2780645631 @default.
• W3088446089 hasConcept C2780739214 @default.
• W3088446089 hasConcept C2908647359 @default.
• W3088446089 hasConcept C44249647 @default.
• W3088446089 hasConcept C500558357 @default.
• W3088446089 hasConcept C50382708 @default.
• W3088446089 hasConcept C71924100 @default.
• W3088446089 hasConcept C78519656 @default.
• W3088446089 hasConcept C99454951 @default.

• next